Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in JanuaryGlobeNewsWire • 01/05/22
Ocuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic Assets Nyxol® and APX3330GlobeNewsWire • 12/08/21
Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)GlobeNewsWire • 11/23/21
Ocuphire Pharma, Inc. (OCUP) Loses 17.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 11/18/21
Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO MeetingGlobeNewsWire • 11/01/21
Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal DiseasesGlobeNewsWire • 10/07/21
Ocuphire's Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual MeetingGlobeNewsWire • 10/01/21
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate UpdateGlobeNewsWire • 08/12/21
Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal DiseaseGlobeNewsWire • 07/22/21
Ocuphire Pharma Stock Surges After Nyxol Combo Treatment Meets Study Endpoints In Presbyopic PatientsBenzinga • 06/30/21
Ocuphire's VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary EndpointsGlobeNewsWire • 06/30/21
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-MarketGlobeNewsWire • 06/08/21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 06/04/21
Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced MydriasisGlobeNewsWire • 05/20/21
Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of PresbyopiaGlobeNewsWire • 05/18/21